Skip to main content
S&P 5007,713.14+1.91%DOW53,304.58+2.93%NASDAQ25,923.13+2.17%BTC$80,362.00+3.59%ETH$2,423.15+5.62%GOLD$4,079.00+3.52%OIL$87.95-8.47%
Smart Investors Daily
SID Premium
SM

NASDAQ · SMMT

Summit Therapeutics Inc.

Healthcare · Biotechnology

$15.80

Down-$0.08 (-0.48%)

Updated Nov 4, 2026, 5:51 PM

SID Score

4.8/10

Composite research score

Smart Money

59/100

Neutral

Market cap
13.39B
P/E ratio
-14.51
Dividend yield
0.00%
52-week range
$12.07 – $29.23
Volume
6.05M
Avg. volume
3.43M

Price performance · SMMT

SMMT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

SMMT closed at $15.80 after 21 trading sessions, down 8.72% for the selected period.

Last close
$15.80
Period change
-8.72%
Period low
$14.50
Period high
$17.95
Daily close
View OHLC price history
SMMT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$14.93$16.42$14.86$15.806.05M
Nov 2, 2026$15.99$16.03$14.74$14.803.87M
Oct 30, 2026$16.03$16.43$15.565$16.033.51M
Oct 29, 2026$15.80$16.5486$15.75$16.204.42M
Oct 28, 2026$15.19$15.80$15.069$15.773.32M
Oct 27, 2026$14.54$15.38$14.40$15.334.74M
Oct 26, 2026$15.49$15.615$14.37$14.504.78M
Oct 23, 2026$15.46$15.55$15.075$15.473.21M
Oct 22, 2026$15.29$15.70$15.13$15.554.15M
Oct 21, 2026$16.35$16.35$15.72$15.835.37M
Oct 20, 2026$15.50$16.18$15.06$16.096.25M
Oct 19, 2026$14.90$15.77$14.83$15.576.15M
Oct 16, 2026$15.39$15.41$14.56$14.634.33M
Oct 15, 2026$15.09$15.55$15.08$15.374.73M
Oct 14, 2026$15.29$15.565$15.04$15.134.66M
Oct 13, 2026$16.79$16.79$15.465$15.527.13M
Oct 12, 2026$17.475$17.59$17.05$17.134.38M
Oct 9, 2026$17.36$17.62$16.82$17.595.76M
Oct 8, 2026$17.612$17.6359$16.795$17.176.18M
Oct 7, 2026$17.10$18.328$16.98$17.958.18M
Oct 6, 2026$17.49$17.53$16.53$17.315.88M

Latest SMMT news

The latest Smart Investors Daily articles mentioning SMMT.

Stock researchCompany · Overview

SMMT research

Overview

Company profile and research snapshot.

Company profile

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$23.00
Implied upside
—
Analysts
—
SMMT recent ratings
DateFirmRatingTarget
Oct 1, 2026BarclaysEqual-Weight—
Sep 29, 2026CitigroupBuy—
Sep 23, 2026HC Wainwright & Co.Neutral—
Sep 9, 2026JefferiesBuy—
Aug 26, 2026HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

Summit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI Deal

Summit Therapeutics (SMMT) has packed October with pipeline moves, including a new Phase II kidney cancer study, a Phase II/III biliary tract cancer trial and an AI pathology research deal. Those October trial launches and the AI pathology tie-up have landed while Summit Therapeutics’ US$16.20 share price has been choppy, with a 24.42% 90 day share price return suggesting momentum has picked up again. This comes even as the year to date share price return is down 7.53% and the 1 year total...

Yahoo · Oct 25, 2026

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China

MIAMI, October 25, 2026--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today’s Presidential Symposium II at the European Society for Medic

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By